U.S. License Holder:
Date of License:
KINERET (anakinra) is an interleukin-1 receptor antagonist indicated for:
Rheumatoid Arthritis (RA): Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs);
Cryopyrin-Associated Periodic Syndromes (CAPS): Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).